Business Wire

Cirium Enhances Industry-Leading On-Time Performance Advisory Board with Three Esteemed Aviation Leaders

4.12.2024 13:12:00 EET | Business Wire | Press release

Share

Cirium, the world’s most trusted source of aviation analytics, has appointed three prominent aviation experts to its Airline and Airport On-Time Performance Advisory Board. The move underscores Cirium’s commitment to maintaining its position as the global gold standard for airline and airport performance analytics.

As the first and only company to establish an On-Time Performance Advisory Board, Cirium ensures an unbiased, data-driven view of operational excellence. The latest appointments—Eamonn Brennan, Scott McCartney, and Alex de Gunten—bring over 75 years of combined experience, enhancing the board’s mission to uphold Cirium’s reputation as the industry benchmark.

Jeremy Bowen, Cirium CEO, said “Adding Eamonn, Scott, and Alex to our Advisory Board is a confirmation of our unwavering commitment to operational reliability and excellence. Their unique perspectives, spanning safety, operations, performance, journalism, and global airline strategy, will amplify our ability to provide independent, accurate data and insights. Together, we are shaping the future of aviation performance analytics for our partners worldwide.”

Meet the New Advisory Board Members

Eamonn Brennan

Eamonn Brennan joins the board with a distinguished record of leadership in aviation safety, performance, and airspace management. Currently serving as a Non-Executive Director at Ryanair, Brennan was the Director General of EUROCONTROL from 2018 to 2022, steering the organization through pivotal challenges such as the record-setting summer of 2019 and the COVID-19 pandemic. During his tenure, he ensured the resilience of the European Air Traffic Network, overseeing 11 million annual flights.

Previously, Brennan served as Chief Executive of the Irish Aviation Authority (2002–2017), achieving significant advancements in safety, cost efficiency, and airspace management. A pioneer in privatization efforts, he led the Airline Group’s successful bid for the UK’s first partial privatization of an Air Navigation Service Provider. Brennan has also held key leadership roles, including Chairman of CANSO Global and the COOPANS Alliance.

Scott McCartney

Scott McCartney, a renowned aviation journalist and business consultant, brings decades of expertise in analyzing and reporting on industry trends. For over 20 years, he penned The Middle Seat, The Wall Street Journal’s celebrated travel column, where he launched its highly regarded airline performance rankings.

McCartney was part of the Pulitzer Prize-winning team of journalists for its coverage of 9/11 and the author of four acclaimed books. His numerous accolades include the George Polk Award and SABEW’s “Best in Business” honors. Currently, he serves as an adjunct professor at Duke University and hosts Airlines Confidential, a globally recognized business podcast. He also leads Middle Seat LLC, a consultancy specializing in media training and aviation research.

Alex De Gunten

A seasoned aviation executive with a global perspective, Alex de Gunten joins the board with over 20 years of strategic leadership experience. As Business Development Officer at HEICO Aerospace, he has played a pivotal role in advancing aerospace innovation.

Previously, de Gunten served as Executive Director of the Latin American and Caribbean Air Transport Association (ALTA), fostering collaboration among regional airlines to address industry challenges. He also drove international expansion efforts as Vice President at LAN Chile and Canadian Airlines International. A multilingual leader fluent in English, Spanish, and French, de Gunten is a sought-after speaker and advisor to organizations such as ALTA and TravelX.

Strengthening Cirium’s Advisory Board

Chaired by Cirium CEO Jeremy Bowen, the board now comprises a powerhouse of aviation expertise, including former airline executive Willy Boulter, ACI World Director General Luis Felipe de Oliveira, and Atmosphere Research Group President Henry Harteveldt.

Board member, Mike Malik Cirium’s Chief Marketing Officer also serves as On-Time Committee Chairperson, and Lydia Webb, Cirium’s Marketing Director – Americas & Strategic Programs, is the Board Secretary.

This strengthened board equips Cirium to continue delivering unmatched insights and analytics to airlines, airports, and other stakeholders in the aviation industry.

About Cirium

Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.

Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium® on LinkedIn or visit cirium.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204844057/en/

Contacts

For Cirium media inquiries please contact media@cirium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye